Biocon to launch new drug in July-Sept quarter

MUMBAI Fri Jan 25, 2013 12:11pm IST

Kiran Mazumdar-Shaw, chairman and managing director of Biocon Ltd., speaks during a news conference in Bangalore March 8, 2007. REUTERS/Jagadeesh Nv/Files

Kiran Mazumdar-Shaw, chairman and managing director of Biocon Ltd., speaks during a news conference in Bangalore March 8, 2007.

Credit: Reuters/Jagadeesh Nv/Files

Related Topics

Stocks

   
Polluted waters of China

Polluted waters of China

Growing cities, overuse of fertilizers, and factory wastewater have degraded China's water supplies to the extent that half the nation's rivers and lakes are severely polluted.  Slideshow 

MUMBAI (Reuters) - Biocon(BION.NS), India's top listed biotech firm, plans to launch psoriasis drug Alzumab in the country in the July-September quarter, a top company executive said on Friday.

The company expects sales of 1 billion rupees from the drug over four years, Kiran Mazumdar-Shaw, chairman, Biocon said in a conference call.

Late on Thursday, Biocon reported an 8.24 percent rise in net profit to 920 million rupees for the Oct-Dec quarter compared with a year earlier.

(Reporting by Kaustubh Kulkarni; Editing by Prateek Chatterjee)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Top News

REUTERS SHOWCASE

Kerry's India Visit

Kerry's India Visit

Kerry presses India on WTO deal ahead of arrival  Full Article 

Big Infra Deal

Big Infra Deal

Piramal, Dutch APG tie up for $1 bln infra investment  Full Article 

E-Commerce

E-Commerce

Amazon says to invest $2 billion more in India   Full Article 

Lupin Results

Lupin Results

Q1 net profit up 56 percent on higher U.S. drug sales   Full Article 

Twitter Results

Twitter Results

Twitter assuages growth concerns for now as shares soar 35 percent  Full Article 

Auto Sector

Auto Sector

VW closes in on Toyota as global auto leader  Full Article 

Fed Meeting

Fed Meeting

Fed seen trimming bond buys, could offer vague rate clues  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage